Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Cisplatin and Vinorelbine in Combination With Cetuximab as First Line Treatment for Patients With Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC): a Single Arm Multicenter Safety Phase 2 Study

NCT01109524 is registered in ClinicalTrials.gov with Eli Lilly and Company as lead sponsor.

NCT NCT01109524
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01109524 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Cisplatin and Vinorelbine in Combination With Cetuximab as First Line Treatment for Patients With Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC): a Single Arm Multicenter Safety Phase 2 Study
Lead sponsor
Eli Lilly and Company
Phase
Phase 2
Overall status
Completed
Start date
July 31, 2010
Completion date
September 30, 2012
Enrollment
72 (actual)
Sites
22

Conditions

As the registry lists them; a condition with its own page is linked.

cancer of the lung, carcinoma, lung neoplasms, non-small-cell lung carcinoma